- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the VEGF pathway in metastatic bladder cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 24, Issue 7, Pages 913-927
Publisher
Informa Healthcare
Online
2015-06-22
DOI
10.1517/13543784.2015.1041588
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma
- (2015) Thomas Geldart et al. EUROPEAN UROLOGY
- EAU Guidelines on Renal Cell Carcinoma: 2014 Update
- (2015) Borje Ljungberg et al. EUROPEAN UROLOGY
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis
- (2014) Martin K Schmid et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Bevacizumab: A Review of Its Use in Advanced Cancer
- (2014) Gillian M. Keating DRUGS
- Circulating tumor cells in early bladder cancer: insight into micrometastatic disease
- (2014) Cristina Raimondi et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
- (2014) Judith Knievel et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Clinical–Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Results From the National Cancer Data Base
- (2014) Phillip J. Gray et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Chemotherapeutic and targeted biological agents for metastatic bladder cancer: A comprehensive review
- (2014) Terence T Sio et al. INTERNATIONAL JOURNAL OF UROLOGY
- A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer
- (2014) Arun A. Azad et al. INVESTIGATIONAL NEW DRUGS
- Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients
- (2014) Cesare Gridelli et al. Journal of Thoracic Oncology
- Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder
- (2014) Brian K McNeil et al. Journal of Translational Medicine
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer
- (2014) M. Chiron et al. MOLECULAR CANCER THERAPEUTICS
- Cabozantinib-Induced Thyroid Dysfunction: A Review of Two Ongoing Trials for Metastatic Bladder Cancer and Sarcoma
- (2014) Sahzene Yavuz et al. THYROID
- Ramucirumab: preclinical research and clinical development
- (2014) Giuseppe Aprile et al. OncoTargets and Therapy
- Characterization of HGF/Met Signaling in Cell Lines Derived From Urothelial Carcinoma of the Bladder
- (2014) Young Lee et al. Cancers
- Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy
- (2013) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
- (2013) Holger Gerullis et al. ANTI-CANCER DRUGS
- Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
- (2013) Susanne Krege et al. BJU INTERNATIONAL
- Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
- (2013) M Santoni et al. BRITISH JOURNAL OF CANCER
- Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy
- (2013) A Necchi et al. BRITISH JOURNAL OF CANCER
- Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
- (2013) Petros D. Grivas et al. CANCER
- Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis
- (2013) Firas Abdollah et al. Cancer Epidemiology
- A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
- (2013) Roberto Pili et al. Clinical Genitourinary Cancer
- Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design
- (2013) Gregory R. Pond et al. Clinical Genitourinary Cancer
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
- (2013) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Sunitinib malate in the treatment of urothelial cancer
- (2013) Francesc Pons et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
- (2013) Arjun V. Balar et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Targeted Therapy for Advanced Urothelial Cancer of the Bladder: Where Do We Stand?
- (2012) Zhaowei Zhu et al. Anti-Cancer Agents in Medicinal Chemistry
- Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer
- (2012) Matthew D. Galsky et al. Clinical Genitourinary Cancer
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
- (2012) Andrea Necchi et al. LANCET ONCOLOGY
- Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer
- (2012) Sabrina Thalita Reis et al. BMC Urology
- Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
- (2011) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer
- (2011) Chen-Yun Yeh et al. BMC CANCER
- Sunitinib in Urothelial Cancer: Clinical, Pharmacokinetic, and Immunohistochemical Study of Predictors of Response
- (2011) David J. Gallagher et al. EUROPEAN UROLOGY
- Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
- (2011) Arnulf Stenzl et al. EUROPEAN UROLOGY
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
- (2011) Noah M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
- (2011) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib Synergizes with Docetaxel in the Treatment of Bladder Cancer Cells
- (2011) Yuan Li et al. UROLOGY
- Angiogenesis as a therapeutic target in urothelial carcinoma
- (2010) Álvaro Pinto et al. ANTI-CANCER DRUGS
- Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells
- (2010) A Rose et al. BRITISH JOURNAL OF PHARMACOLOGY
- A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
- (2010) Srikala S. Sridhar et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer
- (2010) David J. Gallagher et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
- (2010) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
- (2010) Przemyslaw Twardowski et al. UROLOGY
- Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma
- (2009) William E. Osai et al. ANTI-CANCER DRUGS
- Phase 2 trial of sorafenib in patients with advanced urothelial cancer
- (2009) Robert Dreicer et al. CANCER
- Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
- (2009) A. Craig Lockhart et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting angiogenesis in bladder cancer
- (2009) Aymen A. Elfiky et al. Current Oncology Reports
- Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting
- (2008) David J. Gallagher et al. CANCER
- Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model
- (2008) Guru Sonpavde et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The future of tyrosine kinase inhibitors: Single agent or combination?
- (2008) Keith T. Flaherty Current Oncology Reports
- Hypoxia-inducible factor-1 expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma
- (2007) C-Y Chai et al. JOURNAL OF CLINICAL PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started